Pediatric cutaneous lymphomas: rare diseases requiring expert diagnosis and management

References

• Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105, 3768–3785 (2005).
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch. Dermatol. 143, 854–859 (2007).
   PubMed Web of Science ®Google Scholar
• Tsianakas A, Kienast AK, Hoeger PH. Infantile-onset cutaneous T-cell lymphoma. B.r J. Dermatol. 159(6), 1338–1341. (2008).
   PubMed Web of Science ®Google Scholar
• Boccara O, Blanche S, de Prost Y, Brousse N, Bodemer C, Fraitag S. Cutaneous hematologic disorders in children. J. Pediatr. Blood Cancer. 58(2), 226–232 (2012)
   PubMed Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 113(21), 5064–5673 (2009)
   PubMed Web of Science ®Google Scholar
• Fink-Puches R, Chott A, Ardigó M et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr. Dermatol. 21(5), 525–533 (2004).
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br. J. Dermatol. 149(6), 1095–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110, 1713–1722 (2007)
   PubMed Web of Science ®Google Scholar
• Kim YH, Willemze R, Pimpinelli N, Whittaker S et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the of International Society for Cutaneous Lymphomas (ISCL) and the EORTC. Blood 110, 479–484 (2007)
   PubMed Web of Science ®Google Scholar
• Pope E, Weitzman S, Ngan B, Walsh S et al. Mycosis fungoides in the pediatric population: Report from an international Childhood Registry. J. Cut. Med. Surg. 14(1), 1–6 (2003)
   Google Scholar
• Wain EM, Orchard GE, Whittaker SJ, Spittle MF, Russell-Jones R. Outcome in 34 patients with juvenile-onset mycosis fungoides: a clinical, immunophenotypic, and molecular study. Cancer 98(10), 2282–2290 (2003).
   PubMed Web of Science ®Google Scholar
• Ben-Amitai D, Michael D, Feinmesser M, Hodak E. Juvenile mycosis fungoides diagnosed before 18 years of age. Acta. Derm. Venereol. 83(6), 451–456 (2003).
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 28, 4730–4739 (2010).
   PubMed Web of Science ®Google Scholar
• Woringer FR, Kolopp P. Lésion érythémato-squameuse polycyclique de l’avant-bras évoluant depuis 6 ans chez ungarçonnet de 13 ans. Ann. Dermatol. Venereol. 10, 945–948 (1939).
   Google Scholar
• Lee J, Viakhireva N, Cesca C et al. Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. J. Am. Acad. Dermatol. 59(4), 706–712 (2008).
   PubMed Web of Science ®Google Scholar
• Miedler JD, Kristjansson AK, Gould J, Tamburro J, Gilliam AC. Pagetoid reticulosis in a 5-year-old boy. J. Am. Acad. Dermatol. 58(4), 679–681 (2008).
   PubMed Web of Science ®Google Scholar
• Scarabello A, Fantini F, Giannetti A, Cerroni L. Localised pagetoid reticulosis (Woringer-Kolopp disease). Br. J. Dermatol. 14, 806 (2002).
   Google Scholar
• Mendese GW, Beckford A, Krejci N, Mahalingam M, Goldberg L, Gilchrest BA. Pagetoid reticulosis in a prepubescent boy successfully treated with photodynamic therapy. Clin. Exp. Dermatol. 37(7), 759–761 (2012).
   PubMed Web of Science ®Google Scholar
• Zvulunov A, Shkalim V, Ben-Amitai D, Feinmesser M. Clinical and histopathologic spectrum of alopecia mucinosa/follicular mucinosis and its natural history in children. J. Am. Acad. Dermatol. 67(6), 1174–1181 (2012).
   PubMed Web of Science ®Google Scholar
• Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch. Dermatol. 144(6), 738–46 (2008).
   PubMedGoogle Scholar
• Hess Schmid M, Dummer R, Kempf W, Hilty N, Burg G. Mycosis fungoides with mucinosis follicularis in childhood. Dermatology 198(3), 284–287 (1999).
   PubMed Web of Science ®Google Scholar
• Camacho FM, Burg G, Moreno JC, Cámpora RG, Villar JL. Granulomatous slack skin in childhood. Pediatr. Dermatol. 14(3), 204–208 (1997).
   PubMed Web of Science ®Google Scholar
• Moreno-Giménez JC, Jiménez-Puya R, Galán-Gutiérrez M, Pérez-Seoane C, Camacho FM. Granulomatous slack skin disease in a child: the outcome. Pediatr. Dermatol. 24(6), 640–5 (2007).
   PubMed Web of Science ®Google Scholar
• LeBoit PE, Abel EA, Cleary ML et al. Clonal rearrangement of the T cell receptor beta gene in the circulating lymphocytes of erythrodermic follicular mucinosis. Blood 71(5), 1329–1333 (1988).
   PubMed Web of Science ®Google Scholar
• Meister L, Duarte AM, Davis J, Perez JL, Schachner LA. Sézary syndrome in an 11-year-old girl. J. Am. Acad. Dermatol. 28(1), 93–95 (1993).
   PubMed Web of Science ®Google Scholar
• Talpur R, Singh L, Daulat S et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin. Cancer Res. 18(18), 5051–5060 (2012).
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur. J. Cancer. 42, 1014–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Suchin KR, Cucchiara AJ, Gottleib SL et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch. Dermatol. 138, 1054–1060 (2002).
   PubMed Web of Science ®Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 114(20), 4337–4353 (2009).
   PubMed Web of Science ®Google Scholar
• Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95(12), 3653–3661 (2000).
   PubMed Web of Science ®Google Scholar
• de Souza A, Camilleri MJ, Wada DA, Appert DL, Gibson LE, el-Azhary RA. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J. Am. Acad. Dermatol. 61(6), 993–1000 (2009).
   PubMed Web of Science ®Google Scholar
• Van Neer FJ, Toonstra J, Van Voorst Vader PC, Willemze R, Van Vloten WA. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br. J. Dermatol. 144(2), 351–354 (2001).
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Evans AV, Woolford AJ, Black MM, Russell-Jones R. Regional lymphomatoid papulosis: a report of four cases. Br. J. Dermatol. 141(6), 1125–1128 (1999)
   PubMed Web of Science ®Google Scholar
• Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann. NY. Acad. Sci. 941, 59–68 (2001).
   PubMed Web of Science ®Google Scholar
• Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch. Dermatol. 140(3), 306–312 (2004).
   PubMedGoogle Scholar
• Saggini A, Gulia A, Argenyi Z, Fink-Puches R et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am. J. Surg. Pathol. 34(8), 1168–1175 (2010)
   PubMed Web of Science ®Google Scholar
• Yip L, Darling S, Orchard D. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate. Australas J. Dermatol. 52(4), 279–283 (2011).
   PubMed Web of Science ®Google Scholar
• Dupont A. Very late malignant transformation of papular reticulosis with a prolonged development (lymphomatoid papulosis) [in French]. Ann. Dermatol. Syph. 100, 141–146 (1973).
   Google Scholar
• Weinman VF, Ackerman AB. Lymphomatoid papulosis: a critical review and new findings. Am. J. Dermatopathol. 3, 129–163 (1981).
   PubMed Web of Science ®Google Scholar
• Oschlies I, Lisfeld J, Lamant L, Nakazawa A et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 98(1), 50–56 (2013)
   PubMed Web of Science ®Google Scholar
• Kumar S, Pittaluga S, Raffeld M, Guerrera M, Seibel NL, Jaffe ES. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr. Dev. Pathol. 8(1), 52–60 (2005).
   PubMed Web of Science ®Google Scholar
• Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J. Cutan. Pathol. 33( Suppl. 1), 58–70 (2006).
   PubMed Web of Science ®Google Scholar
• Brugieres L, Le Deley MC, Pacquement H et al. CD30+ anaplastic large cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92, 3591–3598 (1998).
   PubMed Web of Science ®Google Scholar
• Bittencourt AL, Barbosa HS, Vieira MD, Farré L. Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases. Acta. Oncol. 48(4), 598–604 (2009).
   PubMed Web of Science ®Google Scholar
• Bittencourt AL, Primo JRL, Oliveira MdeFP. Manifestations of the human T-cell lymphotropic virustype I infection in childhood and adolescence. J. Pediatr. 82, 411–420 (2006)
   Google Scholar
• Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals. Retrovirology 30;9, 46 (2012)
   Google Scholar
• Grubb B, Henderson DB, Pandya AG. Adult T-cell lymphoma/leukemia presenting as pagetoid reticulosis of the palms and soles. J. Am. Acad. Dermatol. 65(5), 1063–1064 (2011).
   PubMed Web of Science ®Google Scholar
• Hodson A, Crichton S, Montoto S et al. Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. J. Clin. Oncol. 29(35), 4696–4701 (2011).
   PubMed Web of Science ®Google Scholar
• Bittencourt AL, Vieira Md, Carvalho EG, Cunha C, Araujo I. Panniculitis-Like T-Cell Lymphoma (SPTL) in a child with spontaneous resolution. Case Rep. Oncol. Med. 2011, 639240 (2011).
   PubMedGoogle Scholar
• Mehta N, Wayne AS, Kim Y et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin. Lymphoma Myeloma. Leuk. 12(1), 20–25 (2012).
   PubMed Web of Science ®Google Scholar
• Hung IJ, Kuo TT, Sun CF. Subcutaneous panniculitic T-cell lymphoma developing in a child with idiopathic myelofibrosis. J. Pediatr. Hematol. Oncol. 21(1), 38–41 (1999).
   PubMed Web of Science ®Google Scholar
• Sangueza M, Plaza JA. Hydroa vacciniforme-like cutaneous T-cell lymphoma: clinicopathologic and immunohistochemical study of 12 cases. J. Am. Acad. Dermatol. 69(1), 112–119 (2013)
   PubMed Web of Science ®Google Scholar
• Burg G, Kempf W, Cozzio A et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J. Cutan. Pathol. 32, 647–674 (2005).
   PubMed Web of Science ®Google Scholar
• Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J. Cutan. Pathol. 24, 457–461 (1997).
   PubMed Web of Science ®Google Scholar
• Goodlad JR, Davidson MM, Hollowood K et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am. J. Surg. Pathol. 24(9), 1279–1285 (2000).
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Melbye M, Munksgaard L et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 111(12), 5524–5549 (2008).
   PubMed Web of Science ®Google Scholar
• Ponzoni M, Ferreri AJ, Mappa S et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist 16(11), 1582–1588 (2011).
   PubMed Web of Science ®Google Scholar
• Sharon V, Mecca PS, Steinherz PG, Trippett TM, Myskowski PL. Two pediatric cases of primary cutaneous B-cell lymphoma and review of the literature. Pediatr. Dermatol. 26(1), 34–39 (2009).
   PubMed Web of Science ®Google Scholar
• Amitay-Laish I, Feinmesser M, Ben-Amitai D et al. Juvenile onset of primary low-grade cutaneous B-cell lymphoma. Br J Dermatol. 161(1), 140–147 (2009).
   PubMed Web of Science ®Google Scholar
• Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch. Dermatol. 141(9), 1139–1145 (2005).
   PubMedGoogle Scholar
• Wilcox RA. Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 88(1), 73–76 (2013).
   PubMed Web of Science ®Google Scholar
• Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control 19(3), 236–44 (2012).
   PubMed Web of Science ®Google Scholar
• Condarco T, Sagatys E, Prakash AV, Rezania D, Cualing H. Primary cutaneous B-cell lymphoma in a child. Fetal. Pediatr. Pathol. 27(4–5), 206–214 (2008).
   PubMed Web of Science ®Google Scholar
• Senff NJ, Zoutman WH, Vermeer MH et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J. Invest. Dermatol. 129(5), 1149–1155 (2009).
   PubMed Web of Science ®Google Scholar
• Murase T, Yamaguchi M, Suzuki R et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109(2), 478–485 (2007).
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Campo E, Seymour JF et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br. J. Haematol. 127, 173–183 (2004).
   PubMed Web of Science ®Google Scholar
• Roglin J, Boer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br. J. Dermatol. 157, 16–25 (2007).
   PubMed Web of Science ®Google Scholar
• Reyes-Castro M, Vega-Memije E. Intravascular large cell lymphoma. Int J Dermatol. 46(6), 619–621 (2007).
   PubMed Web of Science ®Google Scholar
• Park MY, Jung HJ, Park JE, Kim YC. Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab. Eur. J. Dermatol. 20(4), 533–534 (2010).
   PubMed Web of Science ®Google Scholar
• Senff NJ, Noordijk EM, Kim YH et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5), 1600–1609 (2008).
   PubMed Web of Science ®Google Scholar
• Bessell EM, Humber CE, O'Connor S et al. Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification. Br. J. Dermatol. 167(5), 1118–1123 (2012).
   PubMed Web of Science ®Google Scholar
• Martinez-Gonzalez MC, Verea-Hernando MM, Yebra-Pimentel MT, Del Pozo J, Mazaira M, Fonseca E. Imiquimod in mycosis fungoides. Eur. J. Dermatol. 18(2), 148–152 (2008).
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Chapman JT, Dellavalle RP, Zeng C, Aeling JL. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J. Am. Acad. Dermatol. 52(2), 275–280 (2005).
   PubMed Web of Science ®Google Scholar
• Dummer R, Eichmuller S, Gellrich S et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol. Ther. 18(6), 1244–1247 (2010).
   PubMed Web of Science ®Google Scholar
• Jin SP, Jeon YK, Cho KH, Chung JH. Excimer laser therapy (308 nm) for mycosis fungoides palmaris et plantaris: a skin directed and anatomically feasible treatment. Br. J. Dermatol. 163(3), 651–653 (2010).
   PubMed Web of Science ®Google Scholar
• Kontos AP, Kerr HA, Malick F, Fivenson DP, Lim HW, Wong HK. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol. Photoimmunol. Photomed. 22(3), 168–171 (2006).
   PubMed Web of Science ®Google Scholar
• Mori M, Campolmi P, Mavilia L, Rossi R, Cappugi P, Pimpinelli N. Monochromatic excimer light (308 nm) in patch-stage IA mycosis fungoides. J. Am. Acad. Dermatol. 50(6), 943–945 (2004).
   PubMed Web of Science ®Google Scholar
• Meisenheimer JL. Treatment of mycosis fungoides using a 308-nm excimer laser: two case studies. Dermatol. Online J. 12(7), 11 (2006).
   PubMedGoogle Scholar
• Edstrom DW, Hedblad MA. Long-term follow-up of photodynamic therapy for mycosis fungoides. Acta. Derm. Venereol. 88(3), 288–290 (2008).
   PubMed Web of Science ®Google Scholar
• Debu A, Girard C, Kluger N, Guillot B, Dereure O. Topical methyl aminolaevulinate-photodynamic therapy in erosive facial mycosis fungoides. Br. J. Dermatol. 163(4), 884–885 (2010).
   PubMed Web of Science ®Google Scholar
• Park JY, Kim YC. Lichen striatus successfully treated with photodynamic therapy. Clin. Exp. Dermatol. 37(5), 570–572 (2012).
   PubMed Web of Science ®Google Scholar
• Girard C, Debu A, Bessis D, Blatière V, Dereure O, Guillot B. Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children. J. Eur. Acad. Dermatol. Venereol. 27(2), 171–175 (2013)
   Web of Science ®Google Scholar
• Zain J, O’Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest. New Drugs. 28 ( Suppl. 1), S58–S78 (2010).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485–4491 (2010).
   PubMed Web of Science ®Google Scholar
• Witt O, Milde T, Deubzer HE et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukaemia. Klin. Padiatr. 224(6), 398–403 (2012).
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109(11), 4655–4662 (2007).
   PubMed Web of Science ®Google Scholar
• Foss FM, Horwitz SM, Pinter-Brown L et al. Pralatrexate is an effective treatment for heavily pretreated patients with relapsed/refractory transformed mycosis fungoides (tMF). ASH Annual Meeting Abstracts 116(21), 1762 (2010).
   Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin. Oncol. 29(9), 1182–1189 (2011).
   PubMed Web of Science ®Google Scholar
• Ralfkiaer U, Hagedorn PH, Bangsgaard N et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 118(22), 5891–900 (2011).
   PubMed Web of Science ®Google Scholar
• Monsálvez V, Montes-Moreno S, Artiga MJ et al. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod. Pathol. 26(2), 171–181 (2013).
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Imai H et al. Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. Blood 113(5), 1071–1074 (2009).
   PubMed Web of Science ®Google Scholar